
About Rivaara Labs Private Limited
Data last updated:
Rivaara Labs Private Limited is a private limited company based in Mumbai, Maharashtra, India, recognised as a startup by DPIIT. It operates in the diagnostic centers and pathology labs segment of the healthcare sector. It was incorporated on 18 October 2019 and has been in existence for over 7 years.
Its director Gautam Daftary and family are #1,009 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U85300MH2019PTC331867. Its GSTIN is 27AAJCR8676F1ZS (Maharashtra).
The company has an authorised share capital of ₹123 Cr and a paid-up capital of ₹122.14 Cr. It is led by directors including Siddharth Bharat Daftary (Managing Director) and Gautam Vinod Daftary.
Its last annual general meeting (AGM) was held on 22 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 17th Floor Hoechst House Nariman Point, Mumbai, Maharashtra, India – 400021.
As per the financials filed for FY 2026, the company reported a revenue of ₹18.84 Cr, a decline of 26% compared to the previous year. For the same year it recorded a net loss of ₹17.3 Cr (net margin -91.8%) and EBITDA of -₹12.98 Cr (EBITDA margin -68.9%). Revenue has grown at a compounded annual rate (CAGR) of 7% over three years and 31% over five years.
The company has about 143 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 2 brands: Geneilabs and Rivaara Labs. As per MCA filings, the company has satisfied charges of ₹25 Cr on record. Court records list 3 cases involving the company, including 3 filed by the company; 1 case is pending. The company has 10 deals on record (5 funding rounds, 2 rights issues, 2 secondary share transfers), with disclosed funding of ₹160.55 Cr; the latest was in September 2025. Its 6 peer companies in the Healthcare industry (Diagnostics and Pathology Labs), with the same principal business activity (medical and dental practice, nursing, pathology, blood bank services, etc.) are compared by revenue, 2 larger and 4 smaller; the largest is Theism Ceemec Private Limited with revenue of ₹26.01 Cr. The company has 1 MSME Form 1 return on record for the period ending Sep 2021, listing 14 overdue payments to 3 micro and small suppliers.
Rivaara Labs Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0000490). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website rivaaralabs.com.
Company details
Recognitions & Rankings of Rivaara Labs
- Category
- Small (2024-25)
- Udyam number
- UDYAM-MH-19-0000490
- #1,009 Gautam Daftary & family ₹2,700 Cr
Contact details
Rivaara Labs Private Limited's registered office is in Mumbai, Maharashtra. Its website is rivaaralabs.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Apps
- Registered Address17th Floor Hoechst House Nariman Point, Mumbai, Maharashtra, India – 400021
- IndustryHealthcare, Diagnostic Centers & Pathology Labs
To see the full contact details of Rivaara Labs Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Rivaara Labs operates two associated brands: Geneilabs and Rivaara Labs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Develops high-quality reagents for genomic, proteomic research, and custom services. | geneilabs.com | |
| PCR-based test kits are developed for pathogen detection in diagnostics. | rivaaralabs.com |
Business activity
The main business activity of Rivaara Labs is hospital and medical care. In detail, this covers medical and dental practice, nursing, pathology, blood bank services, etc..
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q2 | Medical and dental practice, Nursing, pathology, blood bank services, etc. |
To see the full business activity and turnover split of Rivaara Labs Private Limited, buy the company report.
Financials of Rivaara Labs Private Limited
FY 2025 filings availableRivaara Labs Private Limited reported revenue of ₹18.84 Cr (down 26% YoY) for FY 2026.
Compounded Annual Growth Rate (CAGR)
Revenue fell 26% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 31%. EBITDA rose 1% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹12.98 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹17.3 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -68.9% | ||||
| Net Profit Margin | -91.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Rivaara Labs Private Limited, buy the company report.
Board of directors of Rivaara Labs Private Limited
Rivaara Labs has 3 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Siddharth Bharat Daftary Also directs: Hitech Laboratories Private Limited, Genei Laboratories Private Limited, Aksigen Pharmaceuticals Private Limited and 5 more | Managing Director | 18 Oct 2019 | 7 Years 0 Months | Current |
| Divy Dangi Also directs: Altura Capital Advisors LLP, Authum Realty & Developers LLP, Authum Realty & Construction LLP and 5 more | Nominee Director | 31 Oct 2025 | 0 Years 11 Months | Current |
| Gautam Vinod Daftary Also directs: Iravata Retail Enterprises LLP, Palettier Retail Private Limited, Hitech Laboratories Private Limited and 5 more | Director | 07 Dec 2023 | 2 Years 10 Months | Current |
Peer comparison
Rivaara Labs Private Limited is compared with the 6 companies closest to it by revenue in the Healthcare industry (Diagnostics and Pathology Labs), with the same principal business activity (medical and dental practice, nursing, pathology, blood bank services, etc.), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Theism Ceemec Private Limited | ₹26.01 Cr (FY 2025) | 7.0% | Kolkata, West Bengal, India | |||
| Neuberg Abha Laboratory Private Limited | ₹25.61 Cr (FY 2025) | 7.0% | Surat, Gujarat, India | |||
| Centralab Healthcare Services Private Limited | ₹25.51 Cr (FY 2025) | 45.0% | Mumbai, Maharashtra, India | |||
| Dr. Patel Metropolis Healthcare Private Limited | ₹25.47 Cr (FY 2021) | 68.0% | Mumbai, Maharashtra, India | |||
| Bidyut Prava Healthcare Private Limited | ₹25.36 Cr (FY 2025) | 18.0% | Cuttack, Odisha, India | |||
| Infexn Laboratories Private Limited | ₹25.35 Cr (FY 2024) | 8.0% | Mumbai, Maharashtra, India | |||
| Rivaara Labs Private Limitedthis company | ₹18.84 Cr (FY 2026) | -₹17.3 Cr | -91.8% | -26.0% | 143 | Mumbai, Maharashtra, India |
To see the full peer comparison of Rivaara Labs Private Limited, buy the company report.
Auditor
Rivaara Labs Private Limited is audited by M M Nissim & Co Llp for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| M M Nissim & Co Llp | FY 2023 | 107122W/W100672 |
Shareholding
The shareholding of Rivaara Labs Private Limited is on record for 4 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Promoters | ||||
| Domestic institutional investors (DII) | ||||
| Foreign institutional investors (FII) | ||||
| Public | ||||
| Others |
To see the full shareholding pattern of Rivaara Labs Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 23 Dec 2020 | 100413247 | Hdfc Bank Limited | ₹15 Cr | Satisfied | |
| 23 Dec 2020 | 100413249 | Hdfc Bank Limited | ₹10 Cr | Satisfied |
To see the full charge records of Rivaara Labs Private Limited, buy the company report.
Total charge records: 2 View all charges
Deals & funding
Rivaara Labs Private Limited has 10 deals on record (5 funding rounds, 2 rights issues, 2 secondary share transfers), with disclosed funding of ₹160.55 Cr; the latest was in September 2025.
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2025 | Funding round · Series B | ₹76.99 Cr | Investors: Authum Investment Infrastructure Limited, an individual |
| Aug 2023 | Funding round · Series B | ₹10 Cr | Investors: an individual |
| Jan 2022 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: Leadwood Pharma Ventures LLP |
| Mar 2021 | Rights issue | ₹26.94 Cr | Investors: Leadwood Pharma Ventures LLP , 3 individuals |
| Mar 2020 | Rights issue | ₹2.99 Cr | Investors: Leadwood Pharma Ventures LLP , 2 individuals |
To see the full deal history of Rivaara Labs Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Rivaara Labs Private Limited has 3 court cases on record: 3 filed by Rivaara Labs. 1 case is pending and 2 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 3 | 0 | 1 |
Cases on record (3 of 3)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, BENGALURU, Karnataka | Criminal complaint | Filed by the company against an individual | Pending |
| District court, Ernakulam, Kerala | Civil suit | Filed by the company against an individual | Disposed |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed by the company against an individual | Disposed |
To see the full case history of Rivaara Labs Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Rivaara Labs Private Limited has 1 MSME Form 1 return on record for the period ending Sep 2021, listing 14 overdue payments to 3 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (3 of 3)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Novapure Healthcare | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Rivaara Labs Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Rivaara Labs has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Genei Laboratories Private Limited | U24233KA2013PTC067508 |
To see the full group structure of Rivaara Labs Private Limited, buy the company report.
Employees & EPFO
Rivaara Labs Private Limited has a workforce of 143 employees on its EPFO records as of Apr 06, 2024, across 1 active EPFO establishment.
GST
Rivaara Labs has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAJCR8676F1ZS | Maharashtra | Active | 01 Jan 2020 |
To see the full GST registrations and return filing status of Rivaara Labs Private Limited, buy the company report.
Recent activity
Rivaara Labs Private Limited has 11 board changes on record since 2019: 7 appointments and 4 cessations. The latest: Divy Dangi was appointed as Nominee Director on 31 Oct 2025.
6 earlier events are in the company report.
News
Frequently asked questions
Rivaara Labs is an active private limited company based in Mumbai, Maharashtra, India. The company works in diagnostic centers and pathology labs, within the healthcare industry. It was incorporated on 18 October 2019 (7+ years old) and is registered under CIN U85300MH2019PTC331867.
Rivaara Labs has 3 current directors:
- Siddharth Bharat Daftary - Managing Director
- Divy Dangi - Nominee Director
- Gautam Vinod Daftary - Director
The latest financial statements of Rivaara Labs on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 22 September 2025. Year-wise statements from FY 2020 are in the company report.
The GSTIN of Rivaara Labs is 27AAJCR8676F1ZS, registered in Maharashtra.
The CIN (Corporate Identification Number) of Rivaara Labs is U85300MH2019PTC331867. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Rivaara Labs has 3 court cases on record: 3 filed by the company. 1 is pending.
Rivaara Labs was incorporated on 18 October 2019, making it 7+ years old. It is registered with the Registrar of Companies, Mumbai.
Rivaara Labs has 10 deals on record (5 funding rounds, 2 rights issues, 2 secondary share transfers), with disclosed funding of ₹160.55 Cr; the latest was in September 2025.
The peers of Rivaara Labs by revenue are Theism Ceemec Private Limited, Neuberg Abha Laboratory Private Limited, Centralab Healthcare Services Private Limited, Dr. Patel Metropolis Healthcare Private Limited, Bidyut Prava Healthcare Private Limited and 1 more, all in the Healthcare industry (Diagnostics and Pathology Labs), with the same principal business activity (medical and dental practice, nursing, pathology, blood bank services, etc.).
Divy Dangi was appointed as Nominee Director on 31 Oct 2025. Vaishali Narendra Rathod ceased to be Company Secretary on 30 Nov 2024. Bharat Vinod Daftary ceased to be Whole-Time Director on 07 Dec 2023. Rivaara Labs has 11 board changes on record in total.
Yes, Rivaara Labs is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).
Yes, Rivaara Labs is registered as a small enterprise under Udyam registration (number: UDYAM-MH-19-0000490).